Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Ifosfamin

Ifosfamin: A Detailed Overview

Introduction

Ifosfamin, also known by its more common name Ifosfamide, is a chemotherapy drug used in the treatment of various types of cancer, including soft tissue sarcomas, non-Hodgkin lymphoma, testicular cancer, and others. It belongs to the family of alkylating agents and plays a crucial role in disrupting the DNA of cancer cells, preventing their ability to replicate. Despite its effectiveness, Ifosfamin has a profile of significant side effects, including toxicities that require close management during treatment.

Ifosfamin

Ifosfamin is an alkylating chemotherapy agent, which means it works by adding an alkyl group to the DNA of cancer cells. This interaction interferes with the DNA’s structure and function, ultimately preventing the cancer cells from dividing and replicating. Ifosfamin is chemically related to cyclophosphamide, another alkylating agent, but with a distinct profile of use and toxicity. The compound was developed as a chemotherapy drug to treat a variety of cancers and was first approved in the 1980s. Since then, it has become an essential component of combination chemotherapy regimens, particularly in treating aggressive cancers that do not respond well to other forms of therapy.

Chemical Composition and Structure

Ifosfamin’s molecular formula is C₈H₁₄Cl₂N₂O₂S, and it has a complex structure that includes a mustard group, which is the active part of the molecule responsible for its cytotoxic effects. The drug is a prodrug, meaning that it must undergo conversion in the body into an active form to exert its therapeutic effects. The active metabolites, including ifosfamide mustard, interact with DNA to induce cross-linking, preventing the cell from replicating.

Mechanism of Action

Ifosfamin works as an alkylating agent, which means it binds to the DNA of cancer cells and adds alkyl groups (typically ethyl groups) to the DNA structure. This interaction has several consequences for the cancer cells:

DNA Cross-Linking

The primary mechanism of action of ifosfamin is the formation of DNA cross-links. The alkyl groups bind to both strands of the DNA helix, preventing them from unwinding and replicating. This action impairs the cell's ability to replicate its genetic material, which is crucial for cell division and survival. When the cancer cells attempt to divide, they cannot properly replicate their DNA, leading to the death of the cells.

Inhibition of DNA Repair

Ifosfamin-induced DNA damage activates the cell’s DNA repair machinery, but because of the extensive damage, the repair process is overwhelmed. The damaged DNA cannot be properly repaired, leading to cell cycle arrest and apoptosis (programmed cell death). This is particularly effective against rapidly dividing cancer cells, which are the target of chemotherapy.

Generation of Toxic Metabolites

Once administered, ifosfamin is metabolized in the liver into several active compounds, including ifosfamide mustard. This metabolite is responsible for the drug’s ability to alkylate DNA and cause cellular damage. However, these metabolites are also responsible for much of the drug’s toxicity, especially in tissues such as the bladder and kidneys.

Clinical Uses of Ifosfamin

Ifosfamin is primarily used in the treatment of solid tumors, particularly those that are aggressive or advanced. Its clinical applications have expanded over the years, and it is often used in combination with other chemotherapy agents to enhance efficacy. Some of the most common clinical uses of ifosfamin include:

1. Soft Tissue Sarcomas

One of the most significant uses of ifosfamin is in the treatment of soft tissue sarcomas. These are cancers that arise from the tissues that support, bind, or protect other organs of the body, such as muscles, tendons, fat, and nerves. Soft tissue sarcomas can be difficult to treat, but ifosfamin has shown efficacy in combination with other agents, such as doxorubicin, to reduce tumor size and improve patient outcomes.

2. Non-Hodgkin Lymphoma (NHL)

Non-Hodgkin lymphoma is a cancer of the lymphatic system, and it is often treated with a combination of chemotherapy drugs. Ifosfamin is commonly included in regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and is used in both aggressive and indolent forms of the disease. The drug is effective in shrinking lymph nodes and other involved organs, making it a critical component of the treatment protocol for advanced NHL.

3. Testicular Cancer

Ifosfamin is also used in the treatment of testicular cancer, especially in cases where the disease is advanced or has metastasized. It is part of the VIP (etoposide, ifosfamin, cisplatin) regimen, which is highly effective in treating testicular cancer and achieving long-term remission rates.

4. Other Malignancies

Though less common, ifosfamin may be used to treat other cancers, such as bladder cancer, small cell lung cancer, and breast cancer, particularly in the metastatic setting. Its role is primarily in combination with other agents to increase the overall effectiveness of chemotherapy.

Dosing and Administration

Ifosfamin is administered intravenously (IV) under the supervision of a healthcare provider, typically in a hospital or oncology clinic. The drug is usually given over several hours and can be part of a multi-day infusion protocol.

Standard Dosing Regimens

  • Soft Tissue Sarcomas: A typical dose of 2 to 3 grams per square meter (g/m²) of body surface area, given in 1 to 3 days.

  • Non-Hodgkin Lymphoma: Ifosfamin is typically administered at 1.2 to 2.4 g/m², often as part of combination regimens like CHOP.

  • Testicular Cancer: In combination with other agents, the dosage for VIP treatment may include 1.2 to 1.5 g/m² of ifosfamin.

Supportive Care

Because of the potential for renal toxicity and bladder irritation, patients receiving ifosfamin are typically given additional supportive therapies. These may include hydration to support kidney function and the use of mesna, a drug that protects the bladder from the toxic metabolites of ifosfamin.

Side Effects and Toxicity

Like other chemotherapy drugs, ifosfamin has a range of side effects due to its cytotoxic nature. The most common side effects of ifosfamin include:

1. Hematologic Toxicity

Ifosfamin can cause bone marrow suppression, leading to low levels of red blood cells, white blood cells, and platelets. This can result in:

  • Anemia (fatigue and weakness)

  • Neutropenia (increased risk of infections)

  • Thrombocytopenia (increased risk of bleeding)

2. Gastrointestinal Toxicity

Gastrointestinal symptoms are common, including:

  • Nausea and vomiting (requiring antiemetic therapy)

  • Diarrhea

  • Mucositis (painful inflammation of the mouth and digestive tract)

3. Renal Toxicity

One of the most significant toxicities of ifosfamin is its potential for kidney damage. This is especially concerning in patients with pre-existing renal conditions. Acute renal failure can occur, and close monitoring of kidney function is required during treatment. The use of mesna can help reduce the risk of hemorrhagic cystitis, a complication related to bladder toxicity.

4. Neurotoxicity

Ifosfamin has been linked to central nervous system (CNS) toxicity, with symptoms that can include:

  • Confusion

  • Hallucinations

  • Seizures

This toxicity is dose-dependent and more common in patients with renal impairment.

5. Hemorrhagic Cystitis

Hemorrhagic cystitis, a condition involving bleeding and irritation of the bladder, is a well-known complication of ifosfamin therapy. It occurs due to the accumulation of toxic metabolites in the bladder. Mesna is administered alongside ifosfamin to reduce the risk of this side effect.

Precautions and Contraindications

1. Renal Function

Patients with impaired kidney function are at higher risk for ifosfamin-induced renal toxicity and neurotoxicity. Dosing adjustments may be required, and these patients should be carefully monitored for signs of kidney failure during treatment.

2. Pregnancy and Lactation

Ifosfamin is contraindicated in pregnancy due to its teratogenic potential. It can harm the developing fetus, and women receiving ifosfamin should use effective contraception. It is also contraindicated during breastfeeding, as the drug can pass into breast milk.

3. Bone Marrow Dysfunction

Patients with pre-existing bone marrow suppression or hematologic disorders should be carefully monitored, as ifosfamin can exacerbate bone marrow suppression and increase the risk of severe infections and bleeding.

Conclusion

Ifosfamin is a powerful alkylating chemotherapy agent used in the treatment of several cancers, including soft tissue sarcomas, non-Hodgkin lymphoma, and testicular cancer. While effective, it carries a range of side effects, including hematologic, gastrointestinal, renal, and neurotoxicities. The drug’s potential for toxicity requires close monitoring and supportive care, including the use of mesna to protect against bladder damage and hydration to protect kidney function.